



## Exhibitor & Sponsorship Prospectus

Clinical Multidisciplinary Hematology & Oncology:  
The 20th Annual Review - 2026  
The Westin Kierland Resort & Spa  
April 17, 2026 to April 19, 2026

## Contents

- Welcome
- Benefits of Exhibiting and Sponsoring
- Sponsorship Opportunities
- Non-CME Educational Sessions/Product Theaters
- Exhibit Opportunity
- Rules and Regulations
- W-9

## Dates

April 17, 2026 to April 19, 2026

## Location

The Westin Kierland Resort & Spa  
6902 E. Greenway Parkway  
Scottsdale, AZ 85254

## Course Website

[ce.mayo.edu/hemonc2026](https://ce.mayo.edu/hemonc2026)

## Course Directors

Course Directors

[Allison C. Rosenthal, D.O.](#)

Christina S. Wu, M.B., B.Ch., M.D.

Course Co-Directors

Carol P. Bryant, APRN, D.N.P., ACNP-BC

Farah Raheem, Pharm.D., R.Ph., BCOP

## Key Contact

Morgan Gish

Mayo Clinic School of Continuous

Professional Development (MCSCPD)

200 First St SW, Plummer 2-60

Rochester, MN 55905

[gish.morgan@mayo.edu](mailto:gish.morgan@mayo.edu)

# Clinical Multidisciplinary Hematology & Oncology: The 20th Annual Review - 2026

## Welcome

On behalf of course directors, Allison C. Rosenthal, D.O. and Christina S. Wu, M.B., B.Ch., M.D., and Carol P. Bryant, APRN, D.N.P., ACNP-BCC, we hope you will consider a display opportunity at our Clinical Multidisciplinary Hematology & Oncology: The 20th Annual Review held April 17, 2026 to April 19, 2026, at the Westin Kierland Resort & Spa, Scottsdale, Arizona. We expect 150+ practicing hematologists, medical oncologists, scientists, researchers, nurses, physician assistants, pharmacists, and clinical research associates.

## Course Description

This inaugural CME course covers new diagnostics, therapeutics, and technology for critically ill hematology-oncology patients. It includes multidisciplinary education on organ failure complications, palliative care, healthcare disparities, and ethical issues. Hands-on training in bedside procedures and sessions on team building, negotiation, and conflict management is also included.

## Target Audience

Target audience includes physicians, advanced practice providers, nurses, pharmacists, and respiratory therapists specializing in hematology, oncology, critical care and emergency medicine. Additional specialists who may benefit from this educational content include anesthesiologists, surgeons and hospitalists.

## Exhibit Information

Mayo Clinic recognizes these types of educational programs would not be possible without your support. We invite you to participate in this educational activity with sponsorship. Details are listed below. In support of ACCME guidelines, commercial support will be in a separate area from the educational activity. This event is open to multiple pharmaceutical companies.

To receive a guaranteed space for exhibiting and/or course sponsorship, please complete our letter of agreement Monday, March 8, 2026. For your convenience, Mayo Clinic's Tax ID is 86-0800150

If you have any questions, please feel free to contact us.

Sincerely,  
Susan Reigel  
CME Specialist

Morgan Gish  
Education Administrative Coordinator

# Sponsorship & Exhibit Opportunities

## Daily Product Theatre Sponsorship Levels

Showcase your product offerings to attendees with a product theater.

Breakfast Product Theater - \$20,000 USD (Available April 17, 19, 2026)

Lunch Product Theater - \$20,000 USD (Available April 17, 18, 2026)

Sponsor will be responsible for the following:

- Sponsor is responsible for providing speaker(s), program invitations and advertisements for the product theatre.
- Sponsor is logistically and financially responsible for any/all audiovisual needs for the product theatre.

What is included:

- Product theatre - 45-minute breakfast or lunch session. Complimentary 1,100 sq ft meeting room space and breakfast buffet will be provided by Mayo Clinic.
- Attendee list, networking opportunities, and acknowledgment and recognition at the conference.

The Planning Committee reserves the right to review all submissions before final agreements have been executed. Companies are encouraged to speak on educational topics in addition to products. Please note, audio/visual equipment and fees are the responsibility of the industry supporter. Please email the following information to Morgan Gish, [gish.morgan@mayo.edu](mailto:gish.morgan@mayo.edu), and Susan Reigel, [Reigel.Susan@mayo.edu](mailto:Reigel.Susan@mayo.edu), to receive a Letter of Agreement:

- Company name
- Company contacts (include name and email)
- Summary of Session including any invited speakers

### Platinum Level\* - \$25,000.00 (Two Available)

- Two 6' exhibit table for four representatives (premium location)
- Sponsorship acknowledgement at course through signage and announcements
- Access to networking opportunities throughout the course
- Receive a list of conference attendees on the first day of the course

### Gold Level - \$12,500.00 (Five Available)

- One 6' exhibit table for two representatives (premium location)
- Sponsorship acknowledgement at course through signage and announcements
- Access to networking opportunities throughout the course
- Receive a list of conference attendees on the first day of the course

### Silver Level - \$8,000.00 (Eighteen Available)

- One 6' exhibit table for two representatives (premium location)
- Sponsorship acknowledgement at course through signage and announcements
- Access to networking opportunities throughout the course
- Receive a list of conference attendees on the first day of the course.

### Bronze Level - Exhibit Only - \$4,002.00

- One 6' exhibit table for two representatives (first come, first serve basis)
- Access to networking opportunities throughout the course
- Receive a list of conference attendees on the first day of the course
- Interact face-to-face with course attendees.
- Exhibitors are invited to participate in food and beverage events, including breakfast, lunch, and refreshment breaks.
- A sponsorship acknowledgement on the break slide announcements during the course, in the electronic course syllabus, and during opening/closing remarks.
- Receive an attendee list including registered attendee's name, credentials, city, state on the first day of the course.
- Build visibility for your company in a competitive marketplace.
- Expand your customer base and strengthen existing customer relationships.
- Introduce new products and services

[Click here to secure your Exhibit/Sponsorship](#)

A signed letter of agreement is required to secure your Exhibit/Sponsorship. This is a competitive course. Please consider signing our agreement early to secure Exhibit/Sponsorship.

Set-up: Thursday, April 16<sup>th</sup> – TBD

Exhibit Hours - Friday, April 17<sup>th</sup> at 6:00 am to Sunday, April 19<sup>th</sup> at 12:00 pm

Tear Down: Sunday, April 19<sup>th</sup> – at conclusion of course

## Payment Options:

**PREFERRED Payment: Credit card**

To pay by credit card, please click [here](#)

By Check: Make checks payable to:

Mayo Clinic - MCSCPD

200 First St SW

Plummer 2-60, Attn: Morgan Gish

Rochester, MN 55905

[Reference: Clinical Multi HemOnc 2026](#)

Mayo Clinic Tax ID: 86-0800150

# Clinical Multidisciplinary Hematology & Oncology: The 20th Annual Review – 2026

April 17 – April 19, 2026

Westin Kierland Resort and Spa

Scottsdale, Arizona

*Standard Mountain Time*

## Friday, April 17, 2026

6:00 AM	Registration, Breakfast and Exhibits North Foyer, Northern Sky Terrace, Herberger Ballroom
7:00 AM	Welcome & Introductions Herberger Ballroom
SESSION I MODERATOR	
7:10 AM	<b>Session I Pre-Test</b>
7:25 AM	Smoldering multiple myeloma – to treat or not to treat? <i>Raphael Fonseca, M.D.</i>
7:45 AM	Multiple myeloma in 2026 – incorporating quadruple therapy and novel CELMoDs <b>TBD</b>
8:05 AM	Modern Front-line treatment DLBCL <i>Javier Munoz, M.D., M.B.A.</i>
8:25 AM	CAR-T cell Therapy and Bispecifics: When and for Whom in the Community? <i>Kharfan Dhabaja, M.D., M.B.A.</i>
8:45 AM	<b>Q&amp;A Panel Discussion</b> <i>Raphael Fonseca, M.D., TBD, Javier Munoz, M.D., M.B.A., Kharfan Dhabaja, M.D., M.B.A.</i>
9:05 AM	<b>Session I Post-Test</b>
9:20 AM	<b>Refreshment Break and Exhibits</b>
SESSION II MODERATOR	
9:40 AM	<b>Session II Pre-Test</b>
9:55 AM	Targeted therapies for AML: FLT3 and Menin inhibitors for community clinicians <i>Arana Yi, M.D.</i>
10:15 AM	Sequencing therapies for low risk MDS: imetelstat, luspatercept, HMAs <i>Nathan Punwani, M.D.</i>
10:35 AM	MDS and AML: Risk stratification and Targeted therapy in an evolving landscape <i>Lisa Z. Sproat, M.D.</i>
10:55 AM	Updates in MPNs <i>Jeanne M. Palmer, M.D.</i>
11:15 AM	<b>Q&amp;A Panel Discussion</b> <i>Arana Yi, M.D., Nathan Punwani, M.D., Lisa Z. Sproat, M.D., Jeanne M. Palmer, M.D.</i>
11:35 AM	<b>Session II Post-Test</b>
11:50 AM	<b>Lunch</b> <b>Northern Sky Terrace</b>
SESSION III MODERATOR	Genitourinary cancers
12:50 PM	<b>Session III Pre-Test</b>
1:05 PM	Neoadjuvant therapy in bladder cancer <i>Parminder Singh, M.D.</i>
1:25 PM	Treatment in locally advanced renal cell cancer <i>Yousef Zakharia, M.D.</i>
1:45 PM	Updates on treatment of metastatic prostate cancer

	<i>Shilpa Gupta, M.D. (Cleveland Clinic)</i>
2:05 PM	Tumor board: PARP inhibitors in prostate cancer Parminder Singh (MCA)**, Yousef Zakharia (MCA), Shilpa Gupta (Cleveland Clinic)
2:25 PM	<b>Q&amp;A Panel Discussion</b>
2:45 PM	<b>Session III Post-Test</b>
<b>3:00 PM</b>	<b>Break</b>
<b>SESSION IV MODERATOR</b>	
3:20 PM	<b>Session IV Pre-Test</b>
3:35 PM	Ocular toxicities <b>TBD</b>
3:55 PM	Psychological Needs of the AYA Population <i>Chun Tao, Ph.D., L.P., ABPP</i>
4:15 PM	Beyond diabetes- Understanding cancer therapy induced hyperglycemia <i>Aditi Kumar, M.D. (MCA)</i>
4:35 PM	Fertility Preservation in a Cancer Patient <i>Elysse M. Casson, R.N., O.C.N., Shane T. Lipskind, M.D.</i>
4:55 PM	<b>Q&amp;A Panel Discussion</b> <b>TBD</b> , <i>Chun Tao, Ph.D., L.P., ABPP, Aditi Kumar, M.D. (MCA), Elysse M. Casson, R.N., O.C.N., Shane T. Lipskind, M.D.</i>
5:15 PM	<b>Session IV Post-Test</b>
<b>5:30 PM</b>	<b>Adjourn</b>
<b>6:00 PM</b>	<b>Welcome Reception</b>



# Clinical Multidisciplinary Hematology & Oncology: The 20th Annual Review – 2026

April 17 – April 19, 2026

Westin Kierland Resort and Spa

Scottsdale, Arizona

*Standard Mountain Time*

## Saturday April 18, 2026

6:30 AM	<b>Registration, Breakfast and Exhibits</b> North Foyer, Northern Sky Terrace, Herberger Ballroom
7:30 AM.	<b>Announcements</b> Herberger Ballroom
SESSION V MODERATOR	
7:10 AM	<b>Session V Pre-Test</b>
7:25 AM	Follicular lymphoma: When do you treat and with what? Early vs late relapse <i>Paolo Strati, M.D. (MD Anderson)</i>
7:45 AM	Chronic Lymphocytic Leukemia (CLL): Sequencing Therapy in the BTK and BCL2 inhibitor era <i>Talal Hilal, M.D.</i>
8:05 AM	Future of Radiation- When do we give carbon ion radiation? <i>Sameer R. Keole, M.D.</i>
8:25 AM	<b>Q&amp;A Panel Discussion</b> <i>Paolo Strati, M.D. (MD Anderson), Talal Hilal, M.D., Sameer R. Keole, M.D., Samir H. Patel, M.D.</i>
8:35 AM	<b>Session V Post-Test</b>
8:45 AM	KEYNOTE SPEAKER- AI in Oncology- Transforming Cancer Care <i>Samir H. Patel, M.D.</i>
9:20 AM	<b>Refreshment Break and Exhibits</b>
SESSION VI MODERATOR	
9:40 AM	<b>Session VI Pre-Test</b>
9:55 AM	The Conundrums in managing Cancer-Associated Thrombosis <i>Surbhi Shah, M.B.B.S.</i>
10:15 AM	Immune Thrombocytopenia (ITP): What to do when steroids fail <i>Zoey I. Harris, M.D.</i>
10:35 AM	Anemia in the Older Adult: What's New, What's Missed? <i>Candido E. Rivera, M.D.</i>
10:55 AM	Benign vs Malignant: Interpreting Clonal Hematopoiesis (CHIP CCUS MDS) <i>Abhishek A. Mangaonkar, M.B.B.S.</i>
11:15 AM	<b>Q&amp;A Panel Discussion</b> <i>Surbhi Shah, M.B.B.S., Zoey I. Harris, M.D., Candido E. Rivera, M.D., Abhishek A. Mangaonkar, M.B.B.S.</i>
11:35 AM	<b>Session VI Post-Test</b>
11:50 AM	<b>Lunch</b> Northern Sky Terrace
SESSION VII MODERATOR- Jason Starr (MCF)	Gastrointestinal cancer
12:50 PM	<b>Session VII Pre-Test</b>
1:05 PM	Is there a role for chemotherapy in dMMR stage 3 colon cancer? (Review of NICHE2 vs ATOMIC study) <i>Debate: Jeremy C. Jones, M.D. (MCF) (Yes) vs Kristen K. Ciombor, M.D. (Vanderbilt U) (No)</i>

1:25 PM	Is there a role for immunotherapy in resectable esophageal cancer (Review Keynote 177 and Matterhorn study) <i>Debate: Bassel El-Rayes, M.D. (U of Alabama) (yes) vs Bassam B. Sonbol, M.D. (MCA) (no)</i>
1:45 PM	KRAS inhibitors in GI cancers <i>Tanios S. Bekaii-Saab, M.D.</i>
2:05 PM	Tumor board: Neoadjuvant therapy for locally advanced rectal cancer <i>Mojun Zhu, M.D.</i>
2:25 PM	<b>Q&amp;A Panel Discussion</b> <i>Jeremy C. Jones, M.D, Kristen K. Ciombor, M.D., Bassel El-Rayes, M.D., Bassam B. Sonbol, M.D., Tanios S. Bekaii-Saab, M.D., Mojun Zhu, M.D.</i>
2:45 PM	<b>Session VII Post-Test</b>
<b>3:00 PM</b>	<b>Break</b>
<b>SESSION VIII MODERATOR</b>	
3:20 PM	<b>Session VIII Pre-Test</b>
3:35 PM	Updates in metastatic GYN cancers -Immunotherapy and antibody-drug conjugates <b>TBD</b>
3:55 PM	Integrative Oncology- Myths and truths of febendazole, ivermectin, methylene blue, and other supplements <i>Kristina Gowan, D.O. (City of Hope, Duarte)</i>
4:15 PM	Structured exercise to reduce recurrence of colon cancer- the CHALLENGE study <i>Daniel H. Ahn, D.O.</i>
4:35 PM	Updates in Supportive care treatments <i>Cassia R. Griswold, Pharm.D., R.Ph., BCOP</i>
4:55 PM	<b>Q&amp;A Panel Discussion</b> <b>TBD</b> , <i>Kristina Gowan, D.O., Daniel H. Ahn, D.O., Cassia R. Griswold, Pharm.D., R.Ph., BCOP</i>
5:15 PM	<b>Session VIII Post-Test</b>
<b>5:30 PM</b>	<b>Adjourn</b>

**Clinical Multidisciplinary Hematology & Oncology: The 20th Annual Review – 2026**  
**April 17 – April 19, 2026**  
**Westin Kierland Resort and Spa**  
**Scottsdale, Arizona**  
*Standard Mountain Time*

**Sunday April 19, 2026**

<b>6:00 AM</b>	<b>Registration, Breakfast and Exhibits</b> <b>North Foyer, Northern Sky Terrace, Herberger Ballroom</b>
<b>7:00 AM</b>	<b>Announcements</b> <b>Herberger Ballroom</b>
<b>SESSION IX MODERATOR</b> Lida Mina (MCA)	<i>Breast cancer</i>
<b>7:10 AM</b>	<b>Session IX Pre-Test</b>
<b>7:25 AM</b>	Treating HR+ metastatic breast cancer therapy, beyond first-line (SERENA-6 study) <i>Lida A. Mina, M.D.</i>
<b>7:45 AM</b>	De-escalating treatment in early stage HER2 + breast cancer <i>Shakeela W. Bahadur, M.D.</i>
<b>8:05 AM</b>	Debate: MRD testing is important in breast cancer care <i>Felipe Batalini, M.D. (Yes) vs Christos Vaklavas, M.D. (U of Utah) (No)</i>
<b>8:25 AM</b>	Personalized treatment in early-stage triple negative breast cancer <i>Pooja P. Advani, M.B.B.S., M.D.</i>
<b>8:45 AM</b>	<b>Q&amp;A Panel Discussion</b> <i>Lida A. Mina, M.D., Shakeela W. Bahadur, M.D., Felipe Batalini, M.D., Christos Vaklavas, M.D, Pooja P. Advani, M.B.B.S., M.D.</i>
<b>9:05 AM</b>	<b>Session IX Post-Test</b>
<b>9:20 AM</b>	<b>Refreshment Break and Exhibits</b>
<b>SESSION X MODERATOR</b> Vinicius Ernani (MCA)	<i>Lung and Head/Neck Cancers</i>
<b>9:40 AM</b>	<b>Session X Pre-Test</b>
<b>9:55 AM</b>	Adjuvant therapy in Head/Neck cancers <i>Ashish V. Chintakuntlawar, M.B.B.S., Ph.D.</i>
<b>10:15 AM</b>	Updates on treatment in small cell lung cancer <i>Antonious Z. Hazim, M.D.</i>
<b>10:35 AM</b>	Updates on Targeted Therapies in lung cancer <i>Kathryn A. Gold M.D. (UC San Deigo)</i>
<b>10:55 AM</b>	Tumor board: Peri-operative systemic therapy for lung cancer <i>Staci E. Beamer, M.D., Nathan Y. Yu, M.D., Skyler J. Taylor, M.D., Vinicius Ernani, M.D.</i>
<b>11:15 AM</b>	<b>Q&amp;A Panel Discussion</b> <i>Ashish V. Chintakuntlawar, M.B.B.S., Ph.D., Antonious Z. Hazim, M.D., Kathryn A. Gold M.D., Staci E. Beamer, M.D., Nathan Y. Yu, M.D., Skyler J. Taylor, M.D., Vinicius Ernani, M.D.</i>
<b>11:35 AM</b>	<b>Session X Post-Test</b>
<b>11:50 AM</b>	<b>Closing Comments Adjourn</b>

**Request for Taxpayer  
Identification Number and Certification**

Go to [www.irs.gov/FormW9](http://www.irs.gov/FormW9) for instructions and the latest information.

**Give form to the  
requester. Do not  
send to the IRS.**

**Before you begin.** For guidance related to the purpose of Form W-9, see *Purpose of Form*, below.

Print or type. See Specific Instructions on page 3.	<b>1</b> Name of entity/individual. An entry is required. (For a sole proprietor or disregarded entity, enter the owner's name on line 1, and enter the business/disregarded entity's name on line 2.)  Mayo Clinic Arizona
	<b>2</b> Business name/disregarded entity name, if different from above.
	<b>3a</b> Check the appropriate box for federal tax classification of the entity/individual whose name is entered on line 1. Check only <b>one</b> of the following seven boxes.  <input type="checkbox"/> Individual/sole proprietor <input type="checkbox"/> C corporation <input type="checkbox"/> S corporation <input type="checkbox"/> Partnership <input type="checkbox"/> Trust/estate  <input type="checkbox"/> LLC. Enter the tax classification (C = C corporation, S = S corporation, P = Partnership) _____ <b>Note:</b> Check the "LLC" box above and, in the entry space, enter the appropriate code (C, S, or P) for the tax classification of the LLC, unless it is a disregarded entity. A disregarded entity should instead check the appropriate box for the tax classification of its owner.  <input checked="" type="checkbox"/> Other (see instructions)    501 (c) (3) Tax-exempt Nonprofit Corporation
	<b>3b</b> If on line 3a you checked "Partnership" or "Trust/estate," or checked "LLC" and entered "P" as its tax classification, and you are providing this form to a partnership, trust, or estate in which you have an ownership interest, check this box if you have any foreign partners, owners, or beneficiaries. See instructions _____ <input type="checkbox"/>  <b>4</b> Exemptions (codes apply only to certain entities, not individuals; see instructions on page 3):  Exempt payee code (if any)    1  Exemption from Foreign Account Tax Compliance Act (FATCA) reporting code (if any)    A  (Applies to accounts maintained outside the United States.)
	<b>5</b> Address (number, street, and apt. or suite no.). See instructions. 5951 E. Mayo Blvd. <b>6</b> City, state, and ZIP code Phoenix, Arizona 85054 <b>7</b> List account number(s) here (optional)
Requester's name and address (optional)	

**Part I Taxpayer Identification Number (TIN)**

Enter your TIN in the appropriate box. The TIN provided must match the name given on line 1 to avoid backup withholding. For individuals, this is generally your social security number (SSN). However, for a resident alien, sole proprietor, or disregarded entity, see the instructions for Part I, later. For other entities, it is your employer identification number (EIN). If you do not have a number, see *How to get a TIN*, later.

**Note:** If the account is in more than one name, see the instructions for line 1. See also *What Name and Number To Give the Requester* for guidelines on whose number to enter.

<b>Social security number</b>									
			-				-		
<b>or</b>									
<b>Employer identification number</b>									
8	6	-	0	8	0	0	1	5	0

**Part II Certification**

Under penalties of perjury, I certify that:

- The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me); and
- I am not subject to backup withholding because (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and
- I am a U.S. citizen or other U.S. person (defined below); and
- The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.

**Certification instructions.** You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and, generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions for Part II, later.

**Sign Here**    Signature of U.S. person    *Chris Pudwill*

Date 01/06/2025

**General Instructions**

Section references are to the Internal Revenue Code unless otherwise noted.

**Future developments.** For the latest information about developments related to Form W-9 and its instructions, such as legislation enacted after they were published, go to [www.irs.gov/FormW9](http://www.irs.gov/FormW9).

**What's New**

Line 3a has been modified to clarify how a disregarded entity completes this line. An LLC that is a disregarded entity should check the appropriate box for the tax classification of its owner. Otherwise, it should check the "LLC" box and enter its appropriate tax classification.

New line 3b has been added to this form. A flow-through entity is required to complete this line to indicate that it has direct or indirect foreign partners, owners, or beneficiaries when it provides the Form W-9 to another flow-through entity in which it has an ownership interest. This change is intended to provide a flow-through entity with information regarding the status of its indirect foreign partners, owners, or beneficiaries, so that it can satisfy any applicable reporting requirements. For example, a partnership that has any indirect foreign partners may be required to complete Schedules K-2 and K-3. See the Partnership Instructions for Schedules K-2 and K-3 (Form 1065).

**Purpose of Form**

An individual or entity (Form W-9 requester) who is required to file an information return with the IRS is giving you this form because they